Neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) phase II trial - initial oncological outcomes

被引：0
|
作者：
Yang, X. [1 ]
Aslim, E. J. [1 ]
Ngo, N. T. [1 ]
Khor, L. Y. [1 ]
Chong, T. W. [1 ]
Yuen, J. S. P. [1 ]
Tay, K. J. [1 ]
Ho, H. S. S. [1 ]
Lee, L. S. [1 ]
机构：
[1] Singapore Gen Hosp, Singapore, Singapore
来源：
BJU INTERNATIONAL | 2019年 / 123卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
C-10162
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [21] Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
    Shepard, D. R.
    Dreicer, R.
    Garcia, J.
    Elson, P.
    Magi-Galluzzi, C.
    Raghavan, D.
    Stephenson, A. J.
    Klein, E. A.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 1672 - 1677
  • [22] Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
    Smith, Matthew R.
    Antonarakis, Emmanuel S.
    Ryan, Charles J.
    Berry, William R.
    Shore, Neal D.
    Liu, Glenn
    Alumkal, Joshi J.
    Higano, Celestia S.
    Maneval, Edna Chow
    Bandekar, Rajesh
    de Boer, Carla J.
    Yu, Margaret K.
    Rathkopf, Dana E.
    EUROPEAN UROLOGY, 2016, 70 (06) : 963 - 970
  • [23] Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
    Lorenzo Tosco
    Annouschka Laenen
    Thomas Gevaert
    Isabelle Salmon
    Christine Decaestecker
    Elai Davicioni
    Christine Buerki
    Frank Claessens
    Johan Swinnen
    Karolien Goffin
    Raymond Oyen
    Wouter Everaerts
    Lisa Moris
    Gert De Meerleer
    Karin Haustermans
    Steven Joniau
    BMC Cancer, 18
  • [24] Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy COMMENT
    Kelly, William Kevin
    JOURNAL OF UROLOGY, 2009, 181 (04): : 1677 - 1677
  • [25] HEAD TO HEAD COMPARISON OF CONDITIONAL ONCOLOGICAL OUTCOMES AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH INTERMEDIATE AND HIGH RISK PROSTATE CANCER
    Bianchi, Marco
    Fossati, Nicola
    Gandaglia, Giorgio
    Matloob, Rayan
    Abdollah, Firas
    Capitanio, Umberto
    Deho, Federico
    Scattoni, Vincenzo
    Shariat, Shahrokh F.
    Karakiewicz, Pierre
    Montorsi, Francesco
    Briganti, Alberto
    JOURNAL OF UROLOGY, 2015, 193 (04): : E681 - E681
  • [26] Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
    Tosco, Lorenzo
    Laenen, Annouschka
    Gevaert, Thomas
    Salmon, Isabelle
    Decaestecker, Christine
    Davicioni, Elai
    Buerki, Christine
    Claessens, Frank
    Swinnen, Johan
    Goffin, Karolien
    Oyen, Raymond
    Everaerts, Wouter
    Moris, Lisa
    De Meerleer, Gert
    Haustermans, Karin
    Joniau, Steven
    BMC CANCER, 2018, 18
  • [27] ATLAS: A randomized, double-blind, placebo controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.
    Sandler, Howard M.
    McKenzi, Michael R.
    Tombal, Bertrand F.
    Baskin-Bey, Edwina
    Freedland, Stephen J.
    Roach, Mack
    Widmark, Anders
    Bossi, Alberto
    Dicker, Adam
    Wiegel, Thomas
    Shore, Neal D.
    Smith, Matthew Raymond
    Yu, Margaret K.
    Kheoh, Thian
    Thomas, Shibu
    Dearnaley, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] PHASE 2 TRIAL OF NEOADJUVANT LHRH PLUS ESTRAMUSTINE FOR HIGH RISK PROSTATE CANCER FOLLOWED BY RADICAL PROSTATECTOMY
    Koie, Takuya
    Okamoto, Teppei
    Imanishi, Kengo
    Sugiyama, Naoki
    Suzuki, Yuichiro
    Mori, Kazuyuki
    Kudoh, Shigemasa
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kamimura, Noritaka
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2010, 183 (04): : E258 - E258
  • [29] Phase II Trial of Neoadjuvant Docetaxel and Gefitinib Followed by Radical Prostatectomy in Patients With High-Risk, Locally Advanced Prostate Cancer
    Vulky, Jacqueline
    Porter, Christopher
    Isacson, Christina
    Vaughan, Matthew
    Klowski, Paul
    Picozzi, Vincent
    Corman, John
    CANCER, 2009, 115 (04) : 784 - 791
  • [30] Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial
    Kim, William Y.
    Whang, Young E.
    Pruthi, Raj S.
    Baggstrom, Maria Q.
    Rathmell, W. Kimryn
    Rosenman, Julian G.
    Wallen, Eric M.
    Goyal, Lav K.
    Grigson, Gayle
    Watkins, Catharine
    Godley, Paul A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (06) : 608 - 613
12345